Search

Your search keyword '"Kennedy, Oliver"' showing total 232 results

Search Constraints

Start Over You searched for: Author "Kennedy, Oliver" Remove constraint Author: "Kennedy, Oliver"
232 results on '"Kennedy, Oliver"'

Search Results

1. Efficient Approximation of Certain and Possible Answers for Ranking and Window Queries over Uncertain Data (Extended version)

2. Computing expected multiplicities for bag-TIDBs with bounded multiplicities

5. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

7. TreeToaster: Towards an IVM-Optimized Compiler

8. Efficient Uncertainty Tracking for Complex Queries with Attribute-level Bounds (extended version)

10. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

11. Uncertainty Annotated Databases - A Lightweight Approach for Approximating Certain Answers (extended version)

12. Just-in-Time Index Compilation

13. Seasonal patterns in immunotherapy outcomes.

16. Query Log Compression for Workload Analytics

18. Benchmarking Pocket-Scale Databases

19. Summarizing Large Query Logs in Ettu

20. Communicating Data Quality in On-Demand Curation

21. The Exception that Improves the Rule

22. Mimir: Bringing CTables into Practice

26. BarQL: Collaborating Through Change

27. DBToaster: Higher-order Delta Processing for Dynamic, Frequently Fresh Views

28. Inventory Allocation for Online Graphical Display Advertising

30. Liver fibrosis assessed using non-invasive markers and genetic polymorphisms (PNPLA3andTM6SF2) predisposing to liver fibrosis, is associated with hospitalization or death from heart failure: a prospective UK Biobank study

31. Dynamic Approaches to In-Network Aggregation

35. Prognostic and predictive value of metformin in the EORTC 1325/KEYNOTE- 054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

36. Pocket Data: The Need for TPC-MOBILE

37. Prognostic and predictive value of metformin in the European organisation for research and treatment of cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

38. Detecting the Temporal Context of Queries

41. Additional file 8 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

42. Additional file 6 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

43. Additional file 10 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

44. Additional file 5 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

45. Additional file 4 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

46. Additional file 3 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

47. Additional file 2 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

48. Additional file 7 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

49. Additional file 9 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

Catalog

Books, media, physical & digital resources